SQZ Biotechnologies Reports Third Quarter 2023 Financial Res

SQZ® AAC Phase 1 Trial Observed Best Overall Response (BOR) of Stable Disease or Better in 60 Percent (3 of 5) of Treated Patients, Including One Patient with a Confirmed Complete ResponseSQZ® eAPC Phase 1/2 Trial Monotherapy Observed BOR of Stable Disease in 40 Percent (8 of 20) of Treated PatientsReduced Workforce...

Related Keywords

Howard Bernstein , Biotechnologies Company , Exchange Commission , Management Team , Society For Immunotherapy Of Cancer , Company Annual Report On Form , Observed Best Overall Response , Stable Disease , Treated Patients , Including One Patient , Confirmed Complete , Cost Reduction Initiatives , Ongoing Operating Expenses While , Pursues Strategic , Interim Chief Executive Officer , Recent Portfolio , Activating Antigen Carriers , Annual Meeting , Enhanced Antigen Presenting Cell , Cell Squeeze , Private Securities Litigation Reform Act , Annual Report , Consolidated Statements ,